Twinbeech Capital LP Ironwood Pharmaceuticals Inc Transaction History

Twinbeech Capital LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.32 - $15.45 $620,746 - $1.15 Million	74,609 Added 264.96%	102,768 $895,000
Q4 2023 Feb 14, 2024	BUY	$8.79 - $11.51 $247,517 - $324,110	28,159 New	28,159 $322,000
Q1 2023 May 15, 2023	BUY	$10.37 - $12.56 $2.07 Million - $2.51 Million	199,921 New	199,921 $2.1 Million
Q1 2022 May 16, 2022	SELL	$10.61 - $12.88 $1.11 Million - $1.35 Million	-104,627 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$10.86 - $13.95 $1.14 Million - $1.46 Million	104,627 New	104,627 $1.22 Million
Q1 2021 May 17, 2021	SELL	$9.04 - $11.86 $247,912 - $325,248	-27,424 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$9.05 - $12.2 $131,161 - $176,814	14,493 Added 112.08%	27,424 $312,000
Q3 2020 Nov 16, 2020	SELL	$8.99 - $10.74 $126,498 - $151,122	-14,071 Reduced 52.11%	12,931 $116,000
Q2 2020 Aug 14, 2020	BUY	$9.14 - $11.97 $246,798 - $323,213	27,002 New	27,002 $279,000
Q1 2020 May 15, 2020	SELL	$8.58 - $14.01 $151,188 - $246,870	-17,621 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$8.22 - $14.0 $144,844 - $246,694	17,621 New	17,621 $235,000

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $541M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.